Evidence map›Paper›PMID 38349430›Full record

ArticleCancer immunology, immunotherapy : CII2024

Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.

Kathryn Kline, Tim Luetkens, Rima Koka, Michael E Kallen, Wengen Chen, Haroon Ahmad, Destiny Omili, Thierry Iraguha, Etse Gebru, Xiaoxuan Fan and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Kathryn KlineCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Tim LuetkensCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Rima KokaDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Michael E KallenDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Wengen ChenDiagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Haroon AhmadCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Destiny OmiliCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Thierry IraguhaCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Etse GebruCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Xiaoxuan FanCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Alexis MillerDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Nishanthini DishanthanCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Jillian M BakerDepartment of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA.
Kenneth A DietzeDepartment of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA.
Kim G HankeyCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Jean A YaredCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Nancy M HardyCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Aaron P RapoportCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Saurabh DahiyaCancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.
Djordje Atanackovic *Cancer Immunotherapy, Fannie Angelos Cellular Therapeutics GMP Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Bressler Research Building, Room 9-011, 655 W. Baltimore Street, Baltimore, MD, 21201, USA. datanackovic@som.umaryland.edu.
University of Maryland, Baltimore · USU-M Rogel Cancer Center

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
NCI NIH HHS P30 CA134274
6 · The paper itself

Abstract

backgroundAggressive B cell lymphoma with secondary central nervous system (CNS) involvement (SCNSL) carries a dismal prognosis. Chimeric antigen receptor (CAR) T cells (CAR-T) targeting CD19 have revolutionized the treatment for B cell lymphomas; however, only single cases with CNS manifestations successfully treated with CD19 CAR-T have been reported.

methodsWe prospectively enrolled 4 patients with SCNSL into our study to assess clinical responses and monitor T cell immunity.

resultsTwo of four SNCSL patients responded to the CD19-targeted CAR-T. Only one patient showed a substantial expansion of peripheral (PB) CAR-T cells with an almost 100-fold increase within the first week after CAR-T. The same patient also showed marked neurotoxicity and progression of the SNCSL despite continuous surface expression of CD19 on the lymphoma cells and an accumulation of CD4

conclusionsOur results demonstrate expansion and homing of CAR-T cells into the CNS in SNCSL patients. Local production of chemokines such as IP-10 may support CNS infiltration by CAR-T cells but also carry the potential of amplifying local toxicity. Future studies investigating numbers, phenotype, and function of CAR-T in the different body compartments of SNSCL patients receiving CAR-T will help to improve local delivery of "fit" and highly tumor-reactive CAR-T with low off-target reactivity into the CNS.

Indexed as

Central Nervous System NeoplasmsLymphomaReceptors, Chimeric AntigenAntigens, CD19Chemokine CXCL10HumansAntigens, CD19Chemokine CXCL10Receptors, Chimeric AntigenB cell lymphomaCAR-T cellsCNS lymphomaCytokinesNeurotoxicityT cells

Identifiers

PMID38349430
PMCPMC10864416
OpenAlexW4391786172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.